These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 27686747)

  • 1. Neutrophil-to-lymphocyte ratio is a reliable marker of treatment response in rheumatoid arthritis patients during tocilizumab therapy.
    Ghang B; Kwon O; Hong S; Lee CK; Yoo B; Kim YG
    Mod Rheumatol; 2017 May; 27(3):405-410. PubMed ID: 27686747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab equivalently suppresses oxidative stress compared to tocilizumab among well-controlled patients with rheumatoid arthritis.
    Kizaki K; Yamashita F; Hayashi T; Funakoshi N
    Int J Rheum Dis; 2018 Oct; 21(10):1815-1821. PubMed ID: 27778459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between neutrophil-lymphocyte, platelet-lymphocyte ratio and disease activity in rheumatoid arthritis treated with rituximab.
    Sargin G; Senturk T; Yavasoglu I; Kose R
    Int J Rheum Dis; 2018 Dec; 21(12):2122-2127. PubMed ID: 30338636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of neutrophil-to-lymphocyte ratio as a measure of inflammation in rheumatoid arthritis.
    Chandrashekara S; Mukhtar Ahmad M; Renuka P; Anupama KR; Renuka K
    Int J Rheum Dis; 2017 Oct; 20(10):1457-1467. PubMed ID: 28952205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical value of hematological markers in rheumatoid arthritis patients treated with tocilizumab.
    Zhou L; Xiao DM; Qin W; Xie BH; Wang TH; Huang H; Zhao BJ; Han X; Sun QQ; Wu XD; Cen H
    J Clin Lab Anal; 2019 Jun; 33(5):e22862. PubMed ID: 30779461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutrophil- and platelet-to-lymphocyte ratios are correlated with disease activity in rheumatoid arthritis.
    Fu H; Qin B; Hu Z; Ma N; Yang M; Wei T; Tang Q; Huang Y; Huang F; Liang Y; Yang Z; Zhong R
    Clin Lab; 2015; 61(3-4):269-73. PubMed ID: 25974992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil/Lymphocyte Ratio in Patients with Rheumatoid Arthritis Treated with Biological Agents.
    Koiwa M; Goto S; Takahashi K; Kamada T; Takai S; Nakamura H
    J Nippon Med Sch; 2016; 83(3):118-24. PubMed ID: 27430176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overlooked hematological markers of disease activity in rheumatoid arthritis.
    Tekeoğlu İ; Gürol G; Harman H; Karakeçe E; Çiftçi İH
    Int J Rheum Dis; 2016 Nov; 19(11):1078-1082. PubMed ID: 26620362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study.
    Pascart T; Philippe P; Drumez E; Deprez X; Cortet B; Duhamel A; Houvenagel E; Flipo RM
    Int J Rheum Dis; 2016 Nov; 19(11):1093-1102. PubMed ID: 27018857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of the neutrophil-to-lymphocyte ratio for predicting bacterial infection in patients with rheumatoid arthritis receiving Tocilizumab.
    Nagai Y; Yokogawa N; Shimada K; Sugii S
    Rheumatol Int; 2020 Dec; 40(12):2039-2046. PubMed ID: 32965587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants.
    Inciarte-Mundo J; Ruiz-Esquide V; Hernández MV; Cañete JD; Cabrera-Villalba SR; Ramirez J; Yagüe J; Sanmarti R
    Rheumatology (Oxford); 2015 Dec; 54(12):2239-43. PubMed ID: 26242859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remarkable efficacy of tocilizumab for treating rheumatoid arthritis in patients with high platelet counts.
    Matsuno H
    Mod Rheumatol; 2015 Jan; 25(1):38-42. PubMed ID: 25529071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutrophil-lymphocyte ratio, pain perception, and disease activity score may serve as important predictive markers for sustained remission in rheumatoid arthritis.
    Chandrashekara S; Rajendran A; Bai Jaganath A; Krishnamurthy R
    Reumatismo; 2015 Dec; 67(3):109-15. PubMed ID: 26876190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
    Izumi K; Kaneko Y; Hashizume M; Yoshimoto K; Takeuchi T
    PLoS One; 2015; 10(12):e0145468. PubMed ID: 26698858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Association Between Neutrophil/Lymphocyte Ratio and Disease Activity in Rheumatoid Arthritis and Ankylosing Spondylitis.
    Mercan R; Bitik B; Tufan A; Bozbulut UB; Atas N; Ozturk MA; Haznedaroglu S; Goker B
    J Clin Lab Anal; 2016 Sep; 30(5):597-601. PubMed ID: 26666737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab.
    Diaz-Torne C; Ortiz MDA; Moya P; Hernandez MV; Reina D; Castellvi I; De Agustin JJ; Fuente D; Corominas H; Sanmarti R; Zamora C; Cantó E; Vidal S
    Semin Arthritis Rheum; 2018 Jun; 47(6):757-764. PubMed ID: 29157669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.
    Sagawa A
    Mod Rheumatol; 2011 Aug; 21(4):352-8. PubMed ID: 21347804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab.
    Hirata S; Marotta A; Gui Y; Hanami K; Tanaka Y
    Arthritis Res Ther; 2015 Oct; 17():280. PubMed ID: 26449724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of hematologic markers with IL-17 and IL-1 beta in patients with rheumatoid arthritis.
    Sağ S; Sağ MS; Tekeoğlu I; Kamanlı A; Nas K; Acar BA
    J Back Musculoskelet Rehabil; 2018; 31(4):703-707. PubMed ID: 29578474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of tocilizumab in refractory rheumatoid arthritis: a real life cohort from a single centre.
    Addimanda O; Possemato N; Macchioni P; Salvarani C
    Clin Exp Rheumatol; 2014; 32(4):460-4. PubMed ID: 24960220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.